Baird lowered the firm’s price target on Tandem Diabetes (TNDM) to $24 from $33 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results where it appears to be a good start to the year albeit off lowered expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $59 from $58 at Canaccord
- Tandem Diabetes Care: Strong Performance, Promising Outlook, and Buy Rating Affirmed by William Plovanic
- Tandem Diabetes price target lowered to $30 from $36 at Piper Sandler
- Tandem Diabetes price target lowered to $20 from $22 at Wells Fargo
- Tandem Diabetes Care: Strong Q1 Performance Amid Cautious Outlook and Hold Rating